Publications

Teresa Lozano Moreda publications

66 results

2026

  1. Analysis of murine CAR-T cell–mediated cytotoxicity in solid tumor models

    Methods in Cell Biology (Academic Press Inc.), pp. 53-74

  2. Genetically driven immune microenvironment states associate with therapeutic responses in MYD88 mutant lymphomas

    Molecular Cancer, Vol. 25, Núm. 1

  3. Ikaros degradation by mezigdomide reduces T-cell dysfunction and improves the efficacy of antimyeloma T-cell therapies

    Blood, Vol. 148, Núm. 9, pp. 1129-1142

  4. Live-Cell Microscopy for quantitative analysis of CAR T Cell fratricide and immune synapse

    Methods in Cell Biology (Academic Press Inc.), pp. 75-94

  5. MRD dynamics predicts progression and reveals a vulnerable state for immunotherapy interception in multiple myeloma

    Blood

  6. Single-cell multiomics reveals regulatory mechanisms of CAR T-cell persistence and dysfunction in multiple myeloma

    Blood Neoplasia, Vol. 3, Núm. 2

2025

  1. Foxp3 inhibitory peptide encapsulated in a novel CD25-targeted nanoliposome promotes efficient tumor regression in mice

    Acta Pharmacologica Sinica, Vol. 46, Núm. 1, pp. 171-183

  2. Optimizing protocols for human regulatory T isolation, expansion, and characterization

    Methods in Cell Biology (Academic Press Inc.), pp. 59-77

  3. Phosphatidylserine as a tumor target for CAR-T cell therapy

    Journal for ImmunoTherapy of Cancer, Vol. 13, Núm. 2

  4. Reprogramming CAR-T cells: Targeting SLC transporters for tumor microenvironment adaptation

    Pharmacological Research, Vol. 220

  5. Reprogramming glutamine metabolism enhances BCMA-CAR T-cell fitness and therapeutic efficacy in multiple myeloma

    Blood, Vol. 146, Núm. 24, pp. 2931-2944

  6. Targeting FOXP3 in glioblastoma: Blockade of tumor intrinsic effects boosts response to chemo-radiotherapy

    Life Sciences, Vol. 378

2024

  1. AI is a viable alternative to high throughput screening: a 318-target study

    Scientific Reports, Vol. 14, Núm. 1

  2. Correction to: AI is a viable alternative to high throughput screening: a 318-target study (Scientific Reports, (2024), 14, 1, (7526), 10.1038/s41598-024-54655-z)

    Scientific Reports

  3. Tethered IL15-IL15Rα augments antitumor activity of CD19 CAR-T cells but displays long-term toxicity in an immunocompetent lymphoma mouse model

    Journal for immunotherapy of cancer, Vol. 12, Núm. 7

2023

  1. FOXP3 expression diversifies the metabolic capacity and enhances the efficacy of CD8 T cells in adoptive immunotherapy of melanoma

    Molecular Therapy, Vol. 31, Núm. 1, pp. 48-65

  2. Local delivery of optimized nanobodies targeting the PD-1/PD-L1 axis with a self-amplifying RNA viral vector induces potent antitumor responses

    Cancer Letters, Vol. 561

  3. PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells

    Cancer Research, Vol. 83, Núm. 15, pp. 2513-2526

  4. Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma

    Nature Medicine, Vol. 29, Núm. 3, pp. 632-645

  5. The transcriptional regulator Sin3A balances IL-17A and Foxp3 expression in primary CD4 T cells

    EMBO Reports, Vol. 24, Núm. 5